SynthesisJournal for immunotherapy of cancer2026
Locoregional delivery of CAR T cells in high-grade gliomas: a systematic analysis of safety, efficacy, and emerging biomarkers of response.
Synthesis in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants.Cancer biology & therapy · 2026Review
- Recent Locoregional CAR T-Cell Trials for the Treatment of Recurrent Glioblastoma: Implications for Neuro-Oncology Practice.CNS drugs · 2026Review
- Immunotherapy for Diffuse Midline Glioma: From Preclinical Modeling to Clinical Translation.Cancers · 2026Review
- Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundChimeric antigen receptor T-cell (CAR-T) therapy represents a promising frontier in oncology, but its application to high-grade gliomas (HGG) is challenged by the blood-brain barrier, limited efficacy, and significant toxicities associated with systemic administration. Locoregional delivery has the potential to address these shortcomings. This systematic review evaluates the safety and efficacy of locoregional vs systemic CAR-T cell delivery for HGG.
methodsFollowing PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, a total of 112 studies were identified from three separate databases between 2015 and 2024. Of these, 19 articles were assessed for eligibility, resulting in 16 articles meeting the inclusion criteria with 194 treated patients across 14 clinical trials. A comparative meta-analysis was performed to compare the safety and efficacy outcomes of locoregional administration (eg, intracerebroventricular, intratumoral) with systemic (intravenous) delivery. Severe (grade ≥3) adverse event rates and therapeutic responses were pooled to calculate crude incidence, rate ratios, and relative risks (RRs) with 95% CIs. Both fixed-effect and random-effects models were used to evaluate incidence rate ratios.
resultsLocoregional delivery was associated with a markedly improved safety profile, demonstrating an over 60% reduction in the incidence of grade ≥3 adverse events compared with systemic infusion (RR=0.39; 95% CI 0.30 to 0.52; p<0.001). Furthermore, locoregional strategies demonstrated encouraging signals of antitumor activity, including rates of disease responses not widely observed with systemic approaches (RR=3.79; 95% CI 1.23 to 11.70; p<0.05). Locoregional delivery also enables the analysis of cerebrospinal fluid to monitor T-cell trafficking and emerging biomarkers of immune activation.
conclusionIntracranial delivery of CAR-T cells helps overcome key barriers that limit the efficacy and safety of systemic therapy in brain tumors. These findings support a paradigm shift that integrates locoregional delivery techniques as a pivotal component in the design of future CAR-T cell trials, offering a safer and potentially more effective therapeutic approach with greater opportunities for longitudinal sampling for patients with HGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.